Change management: common failures and a checklist for improvement - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Change management: common failures and a checklist for improvement


Pharmaceutical Technology Europe
Volume 22, Issue 5


(PATRICK KALYANAPU/GETTY IMAGES)
In the pharmaceutical industry, a change and deviation management system (CMS) is a central part of the overall quality management system for drug product manufacture — often referred to as the pharmaceutical quality system. In accordance with the ICH Q10 guideline, also supported by the FDA, CMS is one of the four key elements that make up a pharmaceutical quality system (the remaining three elements include process performance and product quality monitoring system; corrective action and preventive action (CAPA) system; management review of process performance and product quality).

According to the FDA and International Conference on Harmonisation (ICH), a formal CMS should be established to evaluate all changes that could affect the production and control of the drug product, intermediate or API in a pharmaceutical manufacturing company. In addition, some level of CMS is also expected by the FDA for the production of clinical supplies; any changes in the production process and product formulation after the production of the phase III clinical batch must be tightly controlled and carefully evaluated from a product equivalency perspective. Significant process, formulation or equipment changes after the production and use of the phase III clinical batch could result in the performance of lengthy and costly bioequivalency and safety studies, and cause a delay in FDA product approval.

FDA requirements and typical failures

Although the cGMP regulation for drug products (21 CFR 211) has no direct reference to change control, change control is implied in 211.100(a) and 211.160(a). 211.100(a) requires that changes in production procedures and process controls be reviewed and approved by the appropriate organisation units and the quality control unit. This was a major component of Warning Letters issued by the FDA between 2007 and 2009. 211.160(a) requires a similar review and approval for changes related to laboratory controls, sampling plans, specifications, and analytical test methods.

The FDA considers change control a very critical GMP compliance issue; therefore it has been one of the main criteria used by the agency in determining their drug inspection depth and coverage, and their decision for follow-up regulatory actions (e.g., Warning Letter issuance). The FDA's strategy for drug inspection and follow-up is evidenced in their systems inspection programme introduced in 2002 for drug product inspection, and in 2006 for API inspection. The FDA compliance programme for drug product inspection (CP7356.002) instructs the FDA investigator to select the comprehensive inspection option when changes have been made that could impact cross-contamination control, or when there had been changes in technology, new facilities or equipment. The FDA compliance programme for API inspection (CP7356.002F) has the same requirements for the performance of a comprehensive inspection, along with additional criteria for changes related to starting materials, intermediates, equipment, facilities, support systems, processing steps, packaging materials or computer software. Both compliance programmes instruct the FDA district office to recommend regulatory actions when there is a pattern of the failure to establish or to follow a CMS.

Typical major GMP deficiencies related to CMS include:

  • The failure to evaluate FDA filing requirements; i.e., whether to file for a prior approval or changes being effected, or to report the change in the next annual report.
  • The failure to file changes with the FDA.
  • The failure to evaluate and/or justify whether equipment/system requalification is needed to support an equipment/system change, and whether process revalidation, stability studies or equivalency studies are required to support a process and/or processing parameter change.
  • The inadequate review and approval of the change by the quality control unit.
  • The FDA expects the intimate involvement of the quality control unit in the change control review and approval process, and usually holds the quality control unit responsible for deficiencies regarding change control, which again can be evidenced in several Warning Letters issued in the past years. One example of this FDA expectation was documented in a Warning Letter issued by the FDA in 2003. A company performed a routine replacement of the filling pump pistons, without filing a change request because it was a "like to like" replacement (which has been a typical industry practice). Although the replacement pistons had the same part number as the original pistons, they were slightly longer. This longer dimension caused the pistons to come into contact with the bottom of the filling blocks, resulting in the generation of metal particles, which contaminated the product batches. This metal contamination resulted in the recall of several product batches and the FDA's issuance of a Warning Letter. The Warning Letter stated that: "Prior to changing the filling line pump parts on the…line, the quality control unit failed to properly assess the impact that the change may have on the product. It is the quality control unit's responsibility to review any change to your manufacturing process and to assure the change will not adversely affect the drug product".


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here